Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.21 USD
Change Today +0.39 / 1.31%
Volume 969.7K
IMS On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ims health holdings inc (IMS) Key Developments

IMS Health Announces Next Generation Multichannel Solution Nexxus Mobile Intelligence 11

IMS Health announced the immediate availability of Nexxus™ Mobile Intelligence 11, the latest generation of its cloud-based CRM solution designed specifically for the Life Sciences industry. As the latest addition to the Nexxus Commercial Application Suite, Nexxus Mobile Intelligence is interoperable with other Nexxus applications, including Nexxus Marketing, and is tightly integrated with the IMS One™ cloud platform making data access and sharing seamless for commercial teams across all of their customer interactions. By drawing from uniquely broad and diverse data sources that include IMS Health, customer and third-party information, Nexxus Mobile Intelligence curates insights that enable commercial teams to create precision conversations across all channels, in every market. The new release allows Life Sciences companies to simplify their IT architecture and provides maximum flexibility to users in the field. With the extension of its underlying platform to support custom applications written in HTML 5, Nexxus Mobile Intelligence allows easy integration of in-house sales applications, and automatically synchronizes data across all devices with enhanced offline functionality. Built around IMS Health’s proprietary solutions for master data management and social listening, Nexxus Mobile Intelligence delivers comprehensive insights that enable predictive marketing. Companies are guided by the industry’s most robust data and analytics to support next steps for productive customer interactions. New features in Nexxus Mobile Intelligence include: Custom App Support for integrating other sales applications, such as expense reporting and scheduling, directly into Nexxus Mobile Intelligence to automate business processes and create a single, seamless CRM solution. Nexxus Mobile Intelligence supports custom applications written in HTML 5, the coding language for structuring and presenting web content, and can therefore be easily integrated with customers’ existing web-enabled commercial processes " resulting in faster go-to-market campaigns and execution. Activity Updates in real time. By synchronizing Microsoft Exchange calendar and activity updates across all devices, Nexxus Mobile Intelligence improves commercial coordination with a single view of all sales activities to drive maximum impact. Offline Access to most Nexxus Mobile Intelligence functions. This benefits customer-facing teams who spend significant time working in locations where connectivity may not be available or secure, or for those working within restricted healthcare environments. Account Base Selling capabilitiesenable enhanced collaboration. In-house support and field sales teams can more efficiently drive the account plan and strategy across an increasingly complex stakeholder landscape.

IMS Health Holdings, Inc. Reports Preliminary and Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Full Year 2015

IMS Health Holdings, Inc. reported Preliminary and unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $742 million against $662 million a year ago. Operating income was $96 million against operating loss of $39 million a year ago. Profit before income taxes was $60 million against loss before income taxes of $359 million a year ago. Net income was $47 million, compared with net loss of $220 million in last year's second quarter. Basic and diluted earnings per share attributable to common shareholders were $0.14 against basic and diluted loss per share attributable to common shareholders of $0.67 a year ago. Adjusted net income was $125 million or $0.37 per diluted share compared to $134 million or $0.39 per diluted share for the same period a year ago. Adjusted EBITDA was $220 million compared to $226 million for the same period a year ago. Net cash provided by operating activities was $186 million against net cash used in operating activities of $126 million a year ago. Capital expenditures were $16 million against $12 million a year ago. Additions to computer software were $30 million against $23 million a year ago. For the six months, the company reported revenue of $1,374 million against $1,307 million a year ago. Operating income was $187 million against $28 million a year ago. Income before income taxes was $118 million against loss before income taxes of $396 million a year ago. Net income was $345 million against net loss of $244 million a year ago. Diluted earnings per share attributable to common shareholders were $1.01 against basic and diluted loss per share attributable to common shareholders of $0.80 a year ago. Net cash provided by operating activities was $215 million against net cash used in operating activities of $229 million a year ago. Capital expenditures were $25 million against $45 million a year ago. Additions to computer software were $53 million against $44 million a year ago. Adjusted net income was $261 million or $0.76 per diluted share compared to $204 million or $0.65 per diluted share for the same period a year ago. Adjusted EBITDA was $436 million compared to $443 million for the same period a year ago. As of June 30, 2015, cash and cash equivalents were $348 million and the principal amount of debt was $4,214 million, resulting in net debt of $3,866 million. For the full-year 2015, the company reaffirms all full-year 2015 guidance on both a reported and a constant currency basis. The company extends its high teen’s cash tax rate guidance by two additional years. The company now expects its cash tax rate to remain in the high teens through mid-2021.

IMS Health Holdings, Inc., Q2 2015 Earnings Call, Jul 31, 2015

IMS Health Holdings, Inc., Q2 2015 Earnings Call, Jul 31, 2015

IMS Health Holdings, Inc. to Report Q2, 2015 Results on Jul 31, 2015

IMS Health Holdings, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 31, 2015

IMS Health and Foundation Medicine Announce Collaboration to Optimize Targeting of Precision Therapies in Oncology

IMS Health and Foundation Medicine, Inc. announced a collaboration to advance the understanding and effectiveness of precision medicines for treating cancer. Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence platform providing clinical and cost-of-care insights with Foundation Medicine’s dynamic knowledgebase of comprehensive cancer genomic profiles, all at the patient-anonymous level. Through the collaboration, IMS Health’s clients will gain unprecedented insights to rapidly assess health outcomes and effectiveness, and to improve cancer care by better connecting patients to the right targeted therapies at the right time. These enhanced oncologic insights will be powered by Evidence 360 and FoundationCORE. Evidence 360 is IMS Health’s scalable and secure RWE platform that helps clients extract, analyze and visualize real-world data to better understand and measure healthcare outcomes. It brings together IMS Health’s vast library of patient-anonymous data with other patient-anonymous sources of health information to help life sciences companies interpret real-world outcomes and better target their commercial efforts. FoundationCORE is a molecular information knowledgebase containing comprehensive cancer genomic information and insights from more than 43,000 clinical cases profiled by Foundation Medicine. FoundationCORE evolves in real-time, informed by every new cancer patient tested with the company’s commercial assays, FoundationOne and FoundationOne Heme.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMS:US $30.21 USD +0.39

IMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Quintiles Transnational Holdings Inc $75.24 USD +1.04
Teradata Corp $29.49 USD -0.26
TransUnion $25.76 USD +0.24
Verisk Analytics Inc $73.94 USD -0.31
View Industry Companies
 

Industry Analysis

IMS

Industry Average

Valuation IMS Industry Range
Price/Earnings 25.5x
Price/Sales 3.7x
Price/Book 6.3x
Price/Cash Flow 12.5x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMS HEALTH HOLDINGS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.